Physician profile
Bryan David Netolicky
NPI 1255405338
$446.52
in general payments reported to CMS, 2019-2025
11 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.85 · 2021: $116 · 2022: $84.18 · 2023: $23.62 · 2024: $58.14 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $210.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $129.37 | 2021-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $113.73 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $53.89 | 2020-2021 | |
| Corium, LLC | $34.35 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $23.88 | 2020-2021 | |
| Brainsway USA INC | $21.32 | 2025 | Deep Tms System |
| Abbvie INC. | $19.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.62 | 2021 | |
| Almatica Pharma LLC | $12.68 | 2022 | |
| Neurocrine Biosciences, INC. | $12.22 | 2021 | |
| Eisai INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Netolicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.